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The uncontrolled proliferation of hematopoietic cells with no capacity to differentiate into mature blood 
cells leads to leukemia. Though considerable amount of work has been done in understanding the 
molecular basis and gene expression profiles of hematologic malignancies viz., chronic lymphocytic 
leukemia (CLL), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL) and acute 
myelogenous leukemia (AML), the role of various underlying genes and mechanisms predisposing the 
disease are poorly understood. To develop the early diagnosis, preventive and therapeutic strategies, 
identification of population specific novel mutations and candidate genes are required. Micro array 
based gene expression profiling was performed for total of 18 samples (4 from each subtype of 
leukemia that is, CLL, CML, ALL, AML and 2 controls) from Indian population using single color 
hybridization. The expression of all genes presented in terms of fold variation was subjected to F-test. 
The microarray data of genes showing differential regulation with respect to the control samples have 
been obtained from total 50, 238 probes covering 14,992 genes on Agilent’s Human 8X60K Array. The 
experiment was conducted with expectation to have similar patterns of result in terms of gene 
expression but it demonstrates statistically significant relationship only among CML and ALL which are 
of myeloid and lymphoid origin, respectively, in contrast to other combinations. Gene expression 
profiles of four subtypes of leukemia were compared to each other to ascertain the overall association 
and significance of genes for occurrence of different types of leukemiawhich would guide in the 
development of common probable biomarkers for leukemias followed by effective diagnosis, prognosis 
and treatment. Based on their geomean fold values, the highly upregulated genes found in this study 
are listed. 
 





Leukemia is an uncontrolled proliferation of hemato-
poietic cells having no capacity to differentiate normally to 
mature blood cells. It is generally classified into myeloid 
and lymphocytic categories based on affected cell 
lineages (Sawyers et al., 1991).  
Several external agents like chemical exposures, 
treatment with chemotherapeutic agents, radiation or 
intrinsic factor like heredity have been entailed for the 
development of leukemia (Smith and Zhang, 1998). 
Human T-cell leukemia/-lymphotropic virus type I (HTLV-
1) is also a well-empathised cause of adult T-cell 
leukemia (Franchini, 1995). Microarray (MA) based gene 
expression analyses has proved to be an important 








furnishing vital information regarding pathogenesis, 
diagnosis and prognosis of leukemias by increasing the 
knowledge on deregulated pathways in leukemia. The 
incisively positioned DNA probes of microarrays are 
projected to specifically supervise the gene expression 
level in parallel processing (Dunphy, 2006). Analyses of 
differences in gene expression at a large scale for cancer 
investigations can be performed by DNA microarray 
technology (Majeti et al., 2009).  
There are several reports of gene expression profiles of 
chronic myelogenous leukemia (CML) (Nowicki et al., 
2003; Cohen  et al., 2001) and acute myelogenous 
leukemia (AML) (Bullinger et al., 2004; Valk et al., 2004) 
in bulk, whereas in few studies individual types of 
leukemia have been directly compared to normal 
hematopoietic cells (Stirewalt  et al., 2008). For the first 
time we are reporting from Indian population about 
comparative gene expression profiles  between four 
major subtypes of leukemia viz. CML, chronic 
lymphocytic leukemia (CLL), AML and acute lymphocytic 
leukemia (ALL) along with controls. 
In case of leukemia, which are normally associated with 
a single gene abnormality viz. a single genemutation like 
C/EBPα, NPMc, FLT3-ITD mutation or a fusion gene due 
to a chromosomal translocation (for example, AML1-
ETO, BCR-ABL) the use of global gene expression 
analysis techniques reserves for a cryptic understanding 
of the cellular consequences and the disease as a whole. 
These techniques have also been used extensively to 
identify prognostic determinants in leukemia patients, as 
well as to better understand the molecular basis of 
response to therapeutic agents in AML (Goswami et al., 
2009). 
Leukemic thymocytes disclosed typical gene expression 
patterns being strongly consociated with specific 
oncogenic transcription factors after being gone through 
microarray studies. Closely related signatures were also 
found in several samples which lacked activation of 
known T-ALL oncogenes. It leads to predict alternative 
oncogenic transcription factors able to initiate gene 
expression showing similar patterns (Ferrando et al., 
2002). Supervised and unsupervised approaches of 
microarray analysis showed a distinctive pattern of gene 
machinery expression of the CLL clone in regression 
(Haslinger et al., 2004). 
Wang et al. (2004) and Zent et al. (2003) reported that 
genes like FGR, PTPN12, IL4R, FCER2 (CD23), 
TMEM1, TNFRSF1B, CHS1, CCR7 and FMOD among 
others were differentially expressed in a consistent 
manner in CLL when compared with tonsillar B 
lymphocytes and plasma cells. The comparative gene 
expression profiling using cDNA micro array analysis  of 




5315 genes of CML and of normal donors revealed at 
least a 4-fold difference in the mean expression of 263 
genes in which 148 up-regulated and 115 down-regulated 
were observed in the CMLs compared with the normal 
specimens (Nowicki et al., 2003). 
Today, genome-wide gene expression profiling based 
on DNA microarrays represents one of the most powerful 
tools in the area of genomics (Liotta and Petricoin, 2000; 
Ramaswamy and Golub, 2002) since it has become 
economically feasible and widely accessible, thereby 
contributing significantly to our understanding of different 
types of cancers (Care et al., 2003; Kiyoi  et al., 1999). 
To gain discernments into the molecular alterations that 
cause different types of leukemia, we accomplished 
genome-wide comparative gene expression profiling of 
sixteen cases representative of four different forms of 
leukemia (four each) and two cases of normal blood 
samples as controls. The comparative analysis of 
leukemia genomes helps in remoulding our knowledge 
and depth in hemato-malignancies that could have major 
implications for clinical translation (Hudson et al., 2010) 
which fulfils the founding concept of The International 
Cancer Genome Consortium. Our study of genomes of 
sixteen leukemia patients emphasizes this evolutionary 
potential, nevertheless profound studies will be required 
to interpret these outcomes to the healthcare domain. 
 
 
MATERIALS AND METHODS 
 
Selection of patients 
 
Clinically diagnosed blood samples of four major subtypes of 
leukemia viz. CML, AML, ALL, CLL were collected after ethical 
clearance and with the informed consent of the patients through 
approved hospitals followed by specific protocols. A total of 18 
blood samples consisting of all the above four major types of 
leukemia, 4 each, with 2 controls were selected for the analysis 
(Table 1). The leukemia blood samples and controls are not age 





Peripheral blood samples (PBC) of 2.5 ml were collected in 
PAXgeneBlood RNA tubes (Cat no. 762165, Qiagen) to prevent the 




RNA extraction and target labeling 
 
Total RNA was extracted from all the blood samples using the 
PAXgene Blood RNA kit (Qiagen Cat.No.762174), according to the 
procedure provided by the manufacturer. The RNA integrity was 
measured using RNA 6000 Nano Lab chip on the 2100
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Abbreviations: HTLV-1, Human T-cell leukemia/lymphotropic virus type I; MA, microarray; CML, chronic myelogenous leukemia; 
AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia; RIN, RNA integrity 
number; DTT, dithiothreitol. 









sex Status and symptoms Type of diagnosis  
Lymphoblast count & other blood 






smear study and 
bone marrow study 
>60-80% Blast cells in TLC*, immature 
cells of WBCs and platelet counts are 
reduced, TLC >15,000/ cm mm 
Combination of daunorubicin(45 mg/m2/ IV**/3 days) and 






Fever, anaemia, enlarge 
lymph glands in children 
Child having >50-60% blast cells in 
TLC, TLC >20,000/cm mm 
Vincristine (1.5 mg/m2), doxorubicin (25 mg/m2), prednisone 
(40 mg/m2),  










>10-30% Blast cells in TLC, basophils 
more and platelet count mostly 
adequate, TLC >15,000/ cm mm 





CLL 58/M  
 
Anaemia, enlarge lymph 
glands in adult patients 
Elderly patients having >60-70%  blast 
cells in TLC, Pro-lymphoblast and 
smudge cells are present, TLC > 
20,000 /cm mm 
Chlorambucil (5-10 mg/5 days/month),  
fludarabine (50 mg tablets/day), CHOP regimen consisting of 
Cyclophosphamide (750 mg/m2/3weeks), doxorubicin (50 
mg/m2), Vincristine (1.5 mg/m2) and prednisone (100mg/m2 




Control 1 23/M - Normal report - 
Control 2 24/F  - Normal report - 
 




Bioanalyser following manufacturer’s protocol. Eppendorf 
UV-VIS Biophotometer was used to assess total RNA 
purity. For micro array based gene expression 
experiments, total RNA showing OD 260/OD280>1.8 and 
OD260/OD270>1.3 was used. The RNA was evaluated to 
be of good quality when the rRNA 285/185 ratios are 
greater than or equal to 1.5 along with the rRNA 
contribution being 30% or more. Additionally, RNA integrity 
number (RIN) should be >7.0. 
Agilent’s Quick-Amp labeling Kit (p/n5190-0442) was 
used for 1st labeling. Briefly, both first and second strand 
cDNA was synthesized by incubating 500 ng of total RNA 
with 1.2 μl of oligo dT-T7 promoter primer in nuclease free 
water at 65°C for 10 min followed by incubation with 4.0 μl 
of 5x first strand buffer, 2 μl of 0.1 M dithiothreitol (DTT), 1 
μl of 10 mM dNTP mix 1 μl of 200 U/μl MMLV-RT and 0.5 
μl of 40 U/μl RNase OUT, at 40°C for 2 h. Immediately 
following cDNA synthesis, the reaction mixture was 
incubated with 2.4 μl of 10 mM Cyanine 3-CTP (Perkin-
Elmer, Boston MA) 20 μl of 4X Transcription buffer, 8 μl of 
NTP mixture, 6 μl of 0.1 M DTT, 0.5 μl of RNase OUT, 0.6 
μl of Inorganic pyrophosphatase, 0.8 μl of TT RNA 
polymerase and 15.3 μl of nuclease free water at 40°C for 
2 h. Qiagen RNeasy mini spin columns were used for 
hybridization. 825 ng of Cyanine 3 labelled cDNA in a 
volume of 41.8 μl was combined with 1.1 μl of 10X blocking 
reagent and 2.2 μl of 25X fragmentation buffer and 
incubated at 60°C for 30 min in the dark.  
The fragmented cDNA was mixed with 5.5 μl of 2X 
hybridization buffer. About 110 μl of the resulting mixture 
was applied to Human 8x15K Array covering 14,992 
genes, (AMADID: 035928) Gene expressions Micro Array 
(Agilent Technologies, USA) and hybridized at 65°C for 17 
h in an Agilent Microarray Hybridization Chamber with 
hybridization oven. After hybridization, the slides were 
washed with Agilent gene expression wash buffer I for 1 
min at room temperature followed by 1 min wash with 
Agilent gene expression wash buffer II at 37°C. Slides 




Hybridization, scanning, and feature extraction  
 
Scanning of hybridized arrays was performed at a 






Figure 1. Clusters for intra array quality control. GeneSpring GX 11.5 software was used for normalization. [Normalization 
being used for QC: 75th percentile shift normalization. Percentile shift normalization was considered as a global 
normalization in which in an array the locations of all the spot intensities are aligned. Each column of the experiment was 
taken independently in this normalization, which further computes the percentile of the expression values for this array, 
throughout all spots (n has a range from 0-100 ; n=50 is the median). Here this value was substracted from the expression 
value of each entity]. ALL, Acute lymphocytic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; CLL, 




resolution of 2 μm on an Agilent DNA Microarray scanner.Agilent 




cDNA microarray data analysis  
 
Feature extracted data were analyzed using GeneSpring GX 
Version 11.5 software from Agilent. Normalization of the data was 
done using per spot per chip intensity dependent lowest 
normalization. Further quality control of normalized data was done 
using correlation based condition tree to eliminate bad experiments. 
One fold and above differentially regulated genes were filtered from 
the data. Differentially regulated genes were clustered by using 
gene tree to identify significant gene expression patterns (Figure 1). 
 
 
Analysis of variance  
 
Comparing the normal blood gene expression profiles with that of 
leukemia gene expression, the data were grouped. The data from 
all types of leukemia blood samples were subjected to F-Test in 
Microsoft Excel 2007. 
 
 
RESULTS AND DISCUSSION 
 
The whole genome sequence consisting of 50238 probes 
were used for comparative gene expression profiling of 
four major subtypes of leukemia viz. CML, AML, CLL and 
ALL by using Human 8X 60 K Array for 16 patient 
samples (4 for each type of leukemia) and 2 normal 
peripheral blood samples. The results were analysed and 
presented in Figure 1 and Table 2. The cluster analysis of 
differentially regulated genes using gene tree is to identify 
significant gene expression patterns (Figure 1). The 
clusters and sub clusters consist of different leukemia 
    
 
 




Table 2. F-test results of all the probes for all types of leukemia. 
 
Properties / variable 
CML vs. AML CML vs. CLL CML vs. ALL AML vs. ALL AML vs. CLL ALL vs. CLL 
Variable1 Variabl2 Variable1 Variable2 Variable1 Variable2 Variable1 Variable2 Variable1 Variable2 Variable1 Variable2 
Mean  0.3825 0.17029 0.3825 -0.17838 0.3825 0.20059 0.20059 0.17029 0.17029 -0.17838 0.20059 -0.17838 
Variance 1.28342 2.08036 1.28342 2.352692 1.28342 0.874957 0.87495 2.08036 2.08036 2.35269 0.87495 2.35269 
Observations 50238 50238 50238 50238 50238 50238 50238 50238 50238 50238 50238 50238 
df 50237 50237 50237 50237 50237 50237 50237 50237 50237 50237 50237 50237 
F 0.61692 0.54551 1.46684 0.42057 0.88425 0.37189 
P(F<=f) one-tail 0 0 0 0 0 0 
F Critical one-tail 0.98542 0.54551 1.014785 0.985429 0.985429 0.985429 
 




samples in a mix pattern. The cluster analysis of 
normal samples has been performed separately. 
Fold variation of all the probes were obtained in 
terms of log in base 2. 
The fold variation in terms of gene expression of 
all the probes were subjected to F-test two 
samples for variance in two groups where each 
type of leukemia is compared to other type and 
produces six different combinations. The analysis 
of variance was carried out with 95% confidence 
and 5% α error (Table 2).  It was found that the 
critical F values in case of CML vs. AML, CML vs. 
CLL, AML vs. ALL, AML vs. CLL and ALL vs. CLL 
were greater than the calculated F-value whereas 
in case of CML vs. ALL the critical F-value of 
1.014786 is smaller than the calculated F value of 
1.466842. The F-test results revealed that there is 
no significant variation among AML and other 
types in terms of whole genome expression 
profiling when all the detected probes were 
compared. Similarly, CLL does not exhibit any 
significant variation in expression profiling with 
other types of leukemia. CML and ALL show no 
significant relationship with AML and CLL but 
have a strong relationship between them as when 
F-test of two samples for variance was calculated, 
that critical F value was found to be smaller than 
the calculated F value. 
The results suggest that there is no significant 
variation between acute myeloid and chronic 
myeloid leukemia which are reported to be 
originated from myeloid line of blood cells. The 
same result has been found for acute lymphocytic 
and chronic lymphocytic leukemia where their 
origin is known to be lymphocytes. Similarly, 
Lymphoid and myeloid line of blood cells were 
compared to each other which render contrastive 
results showing AML vs. CLL to have no 
significant genome wide gene expression 
variation whereas CML vs. ALL are found to 
furnish statistically significant relationship. The 
experiment was designed with expectation to 
have similar patterns of result but it shows 
strikingly different relationships among each other. 
The study can be further advanced by targeting 
few significantly involved genes in different types 
of leukemia to find out any possible association 
among them. The highest upregulated gene found 
in our study was ENST00000376881 that is, 
ZFP57 (zinc finger protein) [Source: HGNC 
Symbol; Acc: 18791] in CML, LOC390413 
(predicted to be similar to 60S ribosomal protein 
L7) in CLL, THC2585201in AML and FOXC1 in 
ALL (Table 3). Any gene(s) found significantly 
pathologically active for more than one type of 
leukemia could be used to design common 
biomarker for early diagnosis. Leukemia and 
lymphoma society facts (2011-2012) has cited 
that, approximately 31 percent of more males are 
living with leukemia than females but this result is 
not ecumenical as one of our previous report 
(Modak et al., 2011) has reported overall male 
female ratio to be 1.8:1 in leukemia cases which 
shows the number of male leukemia patients are 
almost double than that of female patients. In this 
particular study, the ratio between male and 
female of 1:1.3 has been taken for microarray 





This study is first of its kind as per our exhaustive 
literature survey where the four major subtypes of 
leukemia were matched for their individual genetic 
expression to each other as well as to determine 
the overall association among different types of 
leukemia. This would lead to the development of




Table 3.  Few significantly differentially upregulated genes in four leukemia subtypes with respect to clinically tested control blood samples. 
 




mean value > 
7) 
1 GT_44k_24_P153324 LOC390413 Hs.646625 XR_018341 13q22.3 0.02160  7.22 
2 GT_44k_24_P652786 THC2533996 Hs.412370 THC2533996 4p14 0.01856  7.34 
3 GT_44k_24_P76120 THC2474831 - THC2474831 8p21.3 0.00409  7.71 
4 GT_44k_24_P922101 THC2585201 - THC2585201 10q22.1 0.00621  10.44 
5 GT_44k_24_P926058 Y10152 Hs.546246 Y10152 7p15.1 0.00019  7.06 
6 GT_44k_24_P930276 NFE2L1 Hs.514284 L24123 17q21.32 0.00027 Protein dimerization activity 7.06 
7 GT_44k_24_P930551 THC2585049   - THC2585049 16p11.2 0.00145  9.71 
8 GT_HS_44k_1542 SEPP1 Hs.275775 NM_001085486 5p12 0.11471 Selenium binding 7.46 
ALL (geo mean 
value > 4.5) 
1 GT_44k_23_P201179 PHTF1 Hs.655824 NM_006608 1p13.2 0.00548 DNA binding activity 4.57 
2 GT_44k_23_P69652 GPR78 Hs.350588 NM_080819 4p16.1 0.00049 Rhodopsin-like receptor activity 4.61 
3 GT_44k_24_P144666 LOC401975 Hs.647716 XR_017247 1q24.1 0.04224  4.65 
4 GT_44k_32_P205110 FOXC1 Hs.348883 NM_001453 6p25.3 0.03218 Transcription factor binding 4.71 
5 GT_HsapiAK055033_00003099 HsapiAK055033  HsapiAK055033  0.01460  4.54 
CML (geo 
mean value > 
4.5) 
1 GT_44k_23_P6066 CPXM1 Hs.659346 NM_019609 20p13 0.02156 Carboxypeptidase A activity;  4.60 
2 GT_44k_23_P69652 GPR78 Hs.350588 NM_080819 4p16.1 0.00346 Rhodopsin-like receptor activity  4.74 
3 GT_44k_24_P144666 LOC401975 Hs.647716 XR_017247 1q24.1 0.01208  4.87 
4 GT_44k_24_P376451 GDNF Hs.271721 ENST00000381826 5p13.2 0.03209 Growth factor activity 4.56 
5 GT_44k_24_P827491 PA2G4 Hs.524498 NM_006191 12q13.2 0.00249 




6 GT_44k_32_P80245 ENST00000376881 Hs.156326 ENST00000376881 6p22.1 0.01115 Nucleic acid binding; zinc ion binding 5.44 
CLL (geo mean 
value > 7) 
1 GT_44k_23_P255827 FKSG2 Hs.651853 NM_021631 8p12 0.00008  7.01 
2 GT_44k_23_P26854 KIAA0672 Hs.499758 NM_014859 17p12 0.02551 Gtpase activator activity 7.27 
3 GT_44k_24_P144666 LOC401975 Hs.647716 XR_017247 1q24.1 0.00018  8.28 
4 GT_44k_24_P153324 LOC390413 Hs.646625 XR_018341 13q22.3 0.00059  8.96 
5 GT_44k_24_P161914 LOC130728 Hs.549947 XR_019248 2p16.3 0.00058  7.43 
6 GT_44k_24_P652786 THC2533996 Hs.412370 THC2533996 4p14 0.00003  8.83 
7 GT_44k_24_P76120 THC2474831  THC2474831 8p21.3 0.00005  7.91 
8 GT_44k_24_P922101 THC2585201  THC2585201 10q22.1 0.00021  7.32 
9 GT_44k_24_P926058 Y10152 Hs.546246 Y10152 7p15.1 0.00015  7.69 
10 GT_44k_24_P930551 THC2585049  THC2585049 16p11.2 0.00009  7.01 
11 GT_44k_32_P334340 LOC653483 Hs.667982 AB016898 6q27 0.00072 Molecular function 7.27 




common probable biomarkers for proper management of 
different types of leukemia. The significant association 
between CML and ALL could be clinically very useful for 
the trial and administration of drugs. In our study, the 
origin of cells viz. myeloid and lymphoid does not seem to 
be useful to consider as a parameter for treatment of 
leukemia as it varies among different combinations of 
CML vs. CLL, CML vs. AML, CML vs. ALL, AML vs. ALL, 
AML vs. CLL and ALL vs. CLL. Nevertheless, with this 
possibility, we are cognizant that the present study of 
microarray based gene expression profiling conducted by 
us potentially entertains several drawbacks.  
Firstly, differences shown in the expression levels of 
probes of patients among different types of leukemia may 
be affected from different treatments used based on their 
origin or malignancy because a number of literature data 
suggest for the effect of drugs on the expression level of 
most of the distinguished probes or genes (Heuser et al., 
2005; Chiaretti et al., 2004; McWeeney et al., 2010). The 
patients once diagnosed to any type of leukemia cannot 
be left untreated and in this condition, drug-induced 
changes may create problem in investigations into the 
genetic cause of disease transformation using the blood 
sample of such type of patient. Nevertheless, there is no 
such type of scientific data found to prove this 
assumption.  
Additionally, genetic mechanism and upshots 
responsible for the transformation of the disease keep 
taking place during the patients undergoing medication. 
Secondly, we used peripheral blood samples from 
patients of different age and gender. This may give us an 
impression for patient-specific alterations in genetic 
expression. The systematic microarray study of large 
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